This practical and interactive clinical pathway tool will help you to navigate the best practices to reach an accurate diagnosis of late-onset genetic cholestasis and make informed decisions on how to approach treatment both of symptoms and the underlying liver disease.
Throughout the algorithm, our expert faculty, Verena Keitel-Anselmino, Richard Thompson, and Rosa Miquel provide video guidance on key steps and decisions, including when you should consider genetic testing and perhaps re-consider a diagnosis.
The pathway is supplemented with supporting information and resources to aid you in your daily practice.
Register to access
General Information
Release date: July 30, 2025
Estimated time to complete activity: 15 minutes
This algorithm module is available with video and text. The activity is best supported via a computer or mobile device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari.
Target Audience
This activity is primarily aimed at a global audience of adult hepatologists and gastroenterologists, but is relevant to all members of the multidisciplinary team that manages late-onset genetic cholestatic patients.
Educational Objectives
After completing this activity, the participant should be better able to:
- Recognize the different phenotypes and clinical presentations of late-onset genetic cholestasis
- Integrate consensus recommendations and diagnostic tools to accurately diagnose different types of late-onset genetic cholestasis
- Debate best practice for the current and potential future management of different forms of late-onset genetic cholestasis
Faculty
- Verena Keitel-Anselmino (Program Co-director)
Otto von Geuricke University Magdeburg, Germany - Richard Thompson
(Program Co-director), King’s College London, United Kingdom - Rosa Miquel
King’s College London, United Kingdom
Disclosure of Conflicts of Interest
- Verena Keitel-Anselmino
Honoraria/Consultation fees: Mirum, GSK, Albireo/Ipsen, Falk, AstraZeneca
Stocks, shares or equity: Madrigal
Participation in a company sponsored speaker bureau: Falk, AstraZeneca, Ipsen, Mirum, Albireo, GSK, Gilead, MSD, CSL Behring - Richard Thompson
Honoraria or consultation fees: CymaBay, Enanta, Genfit, GSK, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pfizer, 89bio, Zydus, Abbvie, Intercept, Gilead
Honoraria or consultation fees: Mirum, Ipsen, Rectify, Generation Bio, Integra, Spruce, Alnylam, Glycomine
Stocks, shares or equity: Generation Bio, Rectify, Integra Rosa Miquel
Consultant scientific advisory board: Arbormed
